Alzheon, Inc., is a clinical-stage biotechnology company focused on brain health, memory and aging, developing innovative treatments for Alzheimer's disease and other neurodegenerative disorders. Alzheon pursues drug development programs that have previously been tested in extensive efficacy studies in Alzheimer's disease patients and where new insights can be applied. Based on a drug development platform that yields diverse and novel compounds, the company is building a pipeline of innovative drugs to target the underlying pathogenesis of neurodegeneration in order to improve the symptoms and slow the progression of these devastating diseases.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 10/23/13 | undisclosed | Seed | ||
| 04/08/15 | $10,000,000 | Series A |
Ally Bridge Group | undisclosed |
